Kaposi sarcoma-associated herpesvirus: Difference between revisions
From IDWiki
(added a few other clinical manifestations) |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
== Background == |
||
* Seroprevalence |
* Seroprevalence varies by geography and group |
||
** US general population 1-5% |
** US general population 1-5% |
||
** US men who have sex with men 15-20% |
** US men who have sex with men 15-20% |
||
| Line 6: | Line 6: | ||
** Some Mediterranean countries 10-20% |
** Some Mediterranean countries 10-20% |
||
** Sub-Saharan African countries 30-80% |
** Sub-Saharan African countries 30-80% |
||
* Possibly transmitted through saliva or sex |
|||
== Clinical Manifestations == |
== Clinical Manifestations == |
||
* Mostly asymptomatic |
* Mostly asymptomatic |
||
* Primary infection consists of fever, rash, lymphadenopathy, and bone marrow failure, and may rapidly progress to [[Kaposi sarcoma]] |
|||
* [[Kaposi sarcoma]] |
* [[Kaposi sarcoma]] (KS) |
||
** Hyperpigmented macules or nodules |
|||
** Mostly skin but can include mouth, respiratory tract, and GI tract as well |
|||
* Primary effusion lymphoma (PEL) |
* Primary effusion lymphoma (PEL) |
||
** Causes effusions isolated |
** Causes effusions isolated to the pleural, pericardial, or abdominal cavities |
||
** Occasionally causes mass lesions and extracavitary disease within skin, hematopoietic organs, and the GI |
** Occasionally causes mass lesions and extracavitary disease within skin, hematopoietic organs, and the GI tract |
||
* Multicentric Castleman disease (MCD) |
* Multicentric Castleman disease (MCD) |
||
** Causes systemic symptoms including fever and night sweats, generalized adenopathy, fever, and hepatosplenomegaly |
** Causes systemic symptoms including fever and night sweats, generalized adenopathy, fever, and hepatosplenomegaly |
||
* Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS) |
|||
** Like MCD but without pathology demonstrating MCD |
|||
** Patients are often critically ill |
|||
== Management == |
== Management == |
||
* |
* For [[Kaposi sarcoma]] with symptomatic visceral involvement, chemotherapy is recommended |
||
** May be indicated for disseminated cutaneous KS as well |
|||
[[Category:Human herpesviruses]] |
[[Category:Human herpesviruses]] |
||
Revision as of 12:21, 2 October 2022
Background
- Seroprevalence varies by geography and group
- US general population 1-5%
- US men who have sex with men 15-20%
- US MSM with HIV 30-35%
- Some Mediterranean countries 10-20%
- Sub-Saharan African countries 30-80%
- Possibly transmitted through saliva or sex
Clinical Manifestations
- Mostly asymptomatic
- Primary infection consists of fever, rash, lymphadenopathy, and bone marrow failure, and may rapidly progress to Kaposi sarcoma
- Kaposi sarcoma (KS)
- Hyperpigmented macules or nodules
- Mostly skin but can include mouth, respiratory tract, and GI tract as well
- Primary effusion lymphoma (PEL)
- Causes effusions isolated to the pleural, pericardial, or abdominal cavities
- Occasionally causes mass lesions and extracavitary disease within skin, hematopoietic organs, and the GI tract
- Multicentric Castleman disease (MCD)
- Causes systemic symptoms including fever and night sweats, generalized adenopathy, fever, and hepatosplenomegaly
- Kaposi sarcoma-associated herpesvirus inflammatory cytokine syndrome (KICS)
- Like MCD but without pathology demonstrating MCD
- Patients are often critically ill
Management
- For Kaposi sarcoma with symptomatic visceral involvement, chemotherapy is recommended
- May be indicated for disseminated cutaneous KS as well
